Search hospitals > Maryland > Bethesda
American Oncology Partners of Maryland, PA
Claim this profileBethesda, Maryland 20817
Global Leader in Chronic Lymphocytic Leukemia
Global Leader in Lymphoma
Conducts research for Lung Cancer
Conducts research for Multiple Myeloma
Conducts research for Cancer
48 reported clinical trials
4 medical researchers
Summary
American Oncology Partners of Maryland, PA is a medical facility located in Bethesda, Maryland. This center is recognized for care of Chronic Lymphocytic Leukemia, Lymphoma, Lung Cancer, Multiple Myeloma, Cancer and other specialties. American Oncology Partners of Maryland, PA is involved with conducting 48 clinical trials across 93 conditions. There are 4 research doctors associated with this hospital, such as Mark Goldstein, MD, Ralph Boccia, Bruce D Cheson, and Ralph Vincent Boccia.Area of expertise
1Chronic Lymphocytic Leukemia
Global Leader2Lymphoma
Global LeaderCD20 positive
Stage II
Stage III
Top PIs
Mark Goldstein, MDJEM Research Institute5 years of reported clinical research
Expert in Alzheimer's Disease
Studies Dementia
29 reported clinical trials
46 drugs studied
Ralph BocciaAmerican Oncology Partners of Maryland, PA13 years of reported clinical research
Studies Multiple Myeloma
Studies Breast Cancer
16 reported clinical trials
32 drugs studied
Bruce D ChesonAmerican Oncology Partners of Maryland, PA3 years of reported clinical research
Studies Lymphoma
Studies Chronic Lymphocytic Leukemia
5 reported clinical trials
5 drugs studied
Ralph Vincent BocciaAmerican Oncology Partners of Maryland, PA4 years of reported clinical research
Studies Myelodysplastic Syndrome
1 reported clinical trial
2 drugs studied
Clinical Trials running at American Oncology Partners of Maryland, PA
Chronic Lymphocytic Leukemia
Myelofibrosis
Follicular Lymphoma
Lung Cancer
Breast Cancer
Lymphoma
Mixed-Cell Lymphoma
Cancer
Marginal Zone Lymphoma
MALT Lymphoma
BGB-16673
for Chronic Lymphocytic Leukemia
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Recruiting2 awards Phase 34 criteria
Pirtobrutinib vs Ibrutinib
for Chronic Lymphocytic Leukemia
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Recruiting2 awards Phase 3
Venetoclax + Obinutuzumab/Acalabrutinib
for Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 170 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. Participants in Arm A will receive oral venetoclax in combination with IV infused obinutuzumab, with a 5 week venetoclax ramp up. Participants in Arm B will receive oral venetoclax in combination with oral acalabrutinib, with a 5 week venetoclax ramp up. Participants in Arm C and Arm D will receive oral venetoclax in combination with oral acalabrutinib, with differing venetoclax ramp up periods. The total study duration is approximately 28 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at American Oncology Partners of Maryland, PA?
American Oncology Partners of Maryland, PA is a medical facility located in Bethesda, Maryland. This center is recognized for care of Chronic Lymphocytic Leukemia, Lymphoma, Lung Cancer, Multiple Myeloma, Cancer and other specialties. American Oncology Partners of Maryland, PA is involved with conducting 48 clinical trials across 93 conditions. There are 4 research doctors associated with this hospital, such as Mark Goldstein, MD, Ralph Boccia, Bruce D Cheson, and Ralph Vincent Boccia.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.